Johnson & Johnson received U.S. Food and Drug Administration approval Wednesday for its ThermoCool SmartTouch SF platform [1].
The clearance allows the company to deploy an integrated catheter ablation solution designed to treat cardiac arrhythmias. This regulatory milestone expands the company's portfolio of medical devices aimed at improving precision in heart procedures.
The approved system is known as the dual-energy ThermoCool SmartTouch SF platform, or DE STSF [1], [2]. By utilizing a dual-energy approach [2], the technology aims to streamline the ablation process, a procedure used to scar or destroy heart tissue that causes irregular heartbeats.
Johnson & Johnson announced the approval on Wednesday [1]. The company said that the DE STSF platform provides an integrated solution for clinicians performing these complex interventions.
Catheter ablation has become a primary method for managing atrial fibrillation and other arrhythmias. The introduction of the ThermoCool SmartTouch SF platform follows a trend toward integrating sensing and energy delivery into a single device to reduce procedure time and improve patient outcomes.
Company representatives said the platform is now cleared for use in the U.S. market [1], [2]. The FDA approval process ensures that the device meets specific safety and efficacy standards before it can be marketed to healthcare providers.
“Johnson & Johnson (JNJ) announced today that it received FDA approval for its dual-energy ThermoCool SmartTouch SF platform (DE STSF).”
The FDA approval of the DE STSF platform allows Johnson & Johnson to compete more aggressively in the cardiac rhythm management market. By integrating dual-energy capabilities into a single platform, the company is targeting a reduction in the complexity of ablation procedures, which may lead to higher adoption rates among electrophysiologists and improved efficiency in clinical settings.
